| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| Other Sizes |
| Targets |
Neotriptophenolide targets multiple pathways involved in cell proliferation, apoptosis, and immune modulation. It exhibits anticancer activity by suppressing tumor cell growth. The compound also has anti-inflammatory and immunosuppressive effects. Its mechanism involves regulation of signaling pathways that control cell proliferation and apoptosis. As a natural product from Tripterygium species, it shares some properties with other bioactive compounds from this genus.
|
|---|---|
| ln Vitro |
In vitro, neotriptophenolide exhibits anticancer, anti-inflammatory, and immunosuppressive activities. It suppresses tumor cell growth. Its activity is typically evaluated using cell viability and proliferation assays in cancer cell lines. Anti-inflammatory activity is assessed by measuring cytokine production in activated immune cells. Immunosuppressive effects are evaluated in lymphocyte proliferation assays. However, specific IC50 values are not extensively reported in the available literature.
|
| ln Vivo |
In vivo activity of neotriptophenolide has not been extensively characterized in published literature. As a natural product with anticancer and anti-inflammatory properties, it has potential therapeutic applications. Studies suggest it may contribute to the therapeutic effects of Tripterygium wilfordii. However, specific in vivo efficacy data, including dosing regimens and animal models, are not detailed in the available literature. Further studies are needed to fully characterize its in vivo pharmacological profile.
|
| Enzyme Assay |
Cell-free assays for neotriptophenolide involve characterizing its chemical properties and purity. Its identity is confirmed by HPLC, NMR, and mass spectrometry. As a natural product, its ability to inhibit enzymes or modulate protein targets can be assessed using biochemical assays. However, specific cell-free assay protocols for this compound are not extensively documented in the available literature. The compound is typically dissolved in DMSO for assay preparation.
|
| Cell Assay |
In vitro cellular assays for neotriptophenolide typically involve treating cancer cell lines or immune cells with various concentrations of the compound. Cells are incubated for defined periods (24-72 hours). Cell viability is assessed using MTT, CellTiter-Glo, or other standard assays. Apoptosis is evaluated using Annexin V/PI staining and caspase activity assays. Anti-inflammatory activity is assessed by measuring cytokine production. Immunosuppressive effects are evaluated in lymphocyte proliferation assays.
|
| Animal Protocol |
In vivo animal studies for neotriptophenolide are conducted in models of cancer and inflammation. The compound is administered via various routes including oral gavage or intraperitoneal injection. Tumor growth is monitored in cancer models. Inflammatory markers are measured in serum and tissues. However, specific dosing regimens and experimental protocols are not extensively documented in the available literature. Standard protocols for evaluating anticancer and anti-inflammatory agents would typically be employed.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of neotriptophenolide include a molecular weight of 342.43 g/mol and molecular formula C21H26O4. As a natural diterpenoid, it is expected to have moderate oral bioavailability. The compound is typically stored at appropriate conditions as a research reagent. Detailed ADME parameters such as half-life, Cmax, and AUC are not extensively reported in the available literature.
|
| Toxicity/Toxicokinetics |
The toxicity profile of neotriptophenolide has not been extensively characterized in published literature. As a natural product from Tripterygium wilfordii, it may share some toxicological properties with other compounds from this genus, which are known to have dose-dependent toxicities. Standard preclinical safety studies would include acute and sub-chronic toxicity assessments in rodent models. The compound is intended for research use only and not for therapeutic applications.
|
| References | |
| Additional Infomation |
Neotriptophenolide is a tetracyclic diterpenoid compound with the molecular formula C21H26O4, initially isolated from Tripterygium wilfordii and Tripterygium hypoglaucum. It is a plant metabolite. It is a γ-lactone, aromatic ether, phenolic compound, organic heterotetracyclic compound, and tetracyclic triterpenoid. Reports and data exist regarding Neotriptophenolide in Tripterygium wilfordii and Tripterygium hypoglaucum.
Neotriptophenolide is a tetracyclic diterpenoid from Tripterygium wilfordii with anticancer, anti-inflammatory, and immunosuppressive activities. It suppresses tumor cell growth by regulating pathways involved in cell proliferation and apoptosis. Its molecular formula is C21H26O4 with a molecular weight of 342.43 g/mol. Neotriptophenolide is a research tool for studying cancer, inflammation, and immunosuppression. It is not for therapeutic use. |
| Molecular Formula |
C21H26O4
|
|---|---|
| Molecular Weight |
342.428746700287
|
| Exact Mass |
342.183
|
| CAS # |
81827-74-9
|
| PubChem CID |
133766
|
| Appearance |
Yellow to orange solid powder
|
| Density |
1.2±0.1 g/cm3
|
| Boiling Point |
563.2±50.0 °C at 760 mmHg
|
| Flash Point |
200.4±23.6 °C
|
| Vapour Pressure |
0.0±1.6 mmHg at 25°C
|
| Index of Refraction |
1.595
|
| LogP |
3.75
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
25
|
| Complexity |
595
|
| Defined Atom Stereocenter Count |
2
|
| SMILES |
CC(C)C1=CC(=C2C(=C1OC)CC[C@@H]3[C@@]2(CCC4=C3COC4=O)C)O
|
| InChi Key |
YQHBJMHUMJXFDN-KKSFZXQISA-N
|
| InChi Code |
InChI=1S/C21H26O4/c1-11(2)14-9-17(22)18-13(19(14)24-4)5-6-16-15-10-25-20(23)12(15)7-8-21(16,18)3/h9,11,16,22H,5-8,10H2,1-4H3/t16-,21-/m0/s1
|
| Chemical Name |
(3bR,9bS)-9-hydroxy-6-methoxy-9b-methyl-7-propan-2-yl-3,3b,4,5,10,11-hexahydronaphtho[2,1-e][2]benzofuran-1-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~292.03 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (7.30 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (7.30 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.9203 mL | 14.6015 mL | 29.2030 mL | |
| 5 mM | 0.5841 mL | 2.9203 mL | 5.8406 mL | |
| 10 mM | 0.2920 mL | 1.4602 mL | 2.9203 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
